Basic Study
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 14, 2018; 24(14): 1531-1539
Published online Apr 14, 2018. doi: 10.3748/wjg.v24.i14.1531
Punctual mutations in 23S rRNA gene of clarithromycin-resistant Helicobacter pylori in Colombian populations
Andrés Jenuer Matta, Diana Carolina Zambrano, Alvaro Jairo Pazos
Andrés Jenuer Matta, Registro Poblacional de Cáncer de Cali, Department of Pathology, School of Medicine, Universidad del Valle, Cali 760043, Colombia
Andrés Jenuer Matta, Diana Carolina Zambrano, Faculty of Education and Sports Sciences, Institución Universitaria Escuela Nacional del Deporte, Cali 760043, Colombia
Alvaro Jairo Pazos, Department of Biology, Universidad de Nariño, Pasto 520002, Colombia
Author contributions: All authors that were involved in the acquisition and interpretation of the results read and approved the final manuscript; Matta AJ, Zambrano DC and Pazos AJ conducted the microbiological and molecular tests and analyzed the data; Matta AJ, Zambrano DC, Pazos AJ wrote, edited, and revised the manuscript.
Supported by Administrative Department of Science and Innovation of the Republic of Colombia - COLCIENCIAS, No. RC-1106-408-20549; Institución Universitaria Escuela Nacional del Deporte; and Registro Poblacional de Cáncer de Cali, Universidad del Valle, Cali, Colombia.
Institutional review board statement: All procedures involving human participants were reviewed and approved by the Ethics Committee at Universidad del Valle, Cali, Colombia.
Conflict-of-interest statement: The authors declare that there is no conflict of interest related to this study.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Andrés Jenuer Matta, MSc, PhD, Registro Poblacional de Cáncer de Cali, Department of Pathology, School of Medicine, Universidad del Valle, Street 4B No 36-00, Building 116, Floor 4, Cali 760043, Colombia. andres.matta@correounivalle.edu.co
Telephone: +57-2-5185623 Fax: +57-2-3212100-4101
Received: January 20, 2018
Peer-review started: January 22, 2018
First decision: February 6, 2018
Revised: February 25, 2018
Accepted: March 18, 2018
Article in press: March 18, 2018
Published online: April 14, 2018
Processing time: 81 Days and 4.3 Hours
Abstract
AIM

To characterize punctual mutations in 23S rRNA gene of clarithromycin-resistant Helicobacter pylori (H. pylori) and determine their association with therapeutic failure.

METHODS

PCR products of 23S rRNA gene V domain of 74 H. pylori isolates; 34 resistant to clarithromycin (29 from a low-risk gastric cancer (GC) population: Tumaco-Colombia, and 5 from a high-risk population: Tuquerres-Colombia) and 40 from a susceptible population (28 from Tumaco and 12 from Túquerres) were sequenced using capillary electrophoresis. The concordance between mutations of V domain 23S rRNA gene of H. pylori and therapeutic failure was determined using the Kappa coefficient and McNemar’s test was performed to determine the relationship between H. pylori mutations and clarithromycin resistance.

RESULTS

23S rRNA gene from H. pylori was amplified in 56/74 isolates, of which 25 were resistant to clarithromycin (20 from Tumaco and 5 from Túquerres, respectively). In 17 resistant isolates (13 from Tumaco and 4 from Túquerres) the following mutations were found: A1593T1, A1653G2, C1770T, C1954T1, and G1827C in isolates from Tumaco, and A2144G from Túquerres. The mutations T2183C, A2144G and C2196T in H. pylori isolates resistant to clarithromycin from Colombia are reported for the first time. No association between the H. pylori mutations and in vitro clarithromycin resistance was found. However, therapeutic failure of eradication treatment was associated with mutations of 23S rRNA gene in clarithromycin-resistant H. pylori (κ = 0.71).

CONCLUSION

The therapeutic failure of eradication treatment in the two populations from Colombia was associated with mutations of the 23S rRNA gene in clarithromycin-resistant H. pylori.

Keywords: Clarithromycin; In vitro resistance; Point mutation; Helicobacter pylori; Gastric cancer; 23S rRNA

Core tip: Mutations in 23S rRNA gene V domain of Helicobacter pylori (H. pylori) were studied in order to determine their association with therapeutic failure. In clarithromycin-resistant H. pylori isolated from individuals at high-risk of gastric cancer (GC) in Túquerres-Colombia and at low-risk of GC in Tumaco-Colombia, mutations A1593T1, A1653G2, C1770T, C1954T1, and G1827C in isolates from Tumaco, and A2144G from Túquerres were found. Mutations T2183C and C2196T from both cities were not associated with clarithromycin resistance. However, therapeutic failure of eradication treatment in the sampled Colombian populations was associated with mutations of 23S rRNA gene in clarithromycin-resistant H. pylori.